MPV as a Predictor for ACS in Patients With MASLD

NCT07487571 | Not Yet Recruiting

• 1 other identifier: Soh-Med-26-2-10MS
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to evaluate mean platelet volume (MPV) as a predictor of acute coronary syndrome (ACS) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD to evaluate mean platelet volume (MPV) as a predictor of acute coronary syndrome (ACS) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in Sohag University Hospital.

Conditions

Metabolic Dysfunction-Associated Steatotic Liver Disease; Acute Coronary Syndromes (ACS)

Keywords

Mean platelet volume; Cardiovascular risk; Platelet activation; Metabolic syndrome; Liver staetosis

Outcome Measures

Primary Outcomes (1)

• Mean platelet volume as a predictor for acute coronary syndrome in patients with metabolic dysfunction-associated steatotic liver disease

  To evaluate the association between mean platelet volume (MPV) levels and the presence of acute coronary syndrome in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

  At hospital admission / baseline assessment.

Study Arms (2)

Group I: MASLD patients with acute coronary syndrome (ACS).

Group II: MASLD patients without acute coronary syndrome

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population will consist of adult patients diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD) who are admitted to or evaluated at Sohag University Hospital. Eligible participants will include patients with confirmed MASLD based on clinical evaluation, laboratory findings, and imaging studies. The study will include two groups: patients with MASLD who present with acute coronary syndrome (ACS) and patients with MASLD without evidence of ACS. Participants will be recruited from inpatient and outpatient services, including the cardiology and internal medicine departments. Demographic and clinical data, cardiovascular risk factors, and laboratory parameters-including mean platelet volume (MPV)-will be collected at baseline

You may qualify if:

• Adult patients aged ≥18 years.
• Confirmed diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) based on clinical, laboratory, and imaging criteria).
• Patients diagnosed with acute coronary syndrome (unstable angina, NSTEMI, or STEMI) for Group I.
• MASLD patients without clinical or electrocardiographic evidence of acute coronary syndrome for Group II.
• Patients who provide informed consent to participate in the study.

You may not qualify if:

• Patients with chronic liver diseases other than MASLD (e.g., viral hepatitis, autoimmune hepatitis, alcoholic liver disease).
• Patients with known hematological disorders affecting platelet count or function.
• Patients receiving antiplatelet or anticoagulant therapy prior to blood sampling.
• Patients with active infection, inflammatory diseases, or malignancy.
• Patients with chronic kidney disease or end-stage renal failure.
• Pregnant or lactating females.

Sponsors & Collaborators

• Sohag University: lead

Study Sites (1)

Sohag University Hospital

Sohag, Sohag Governorate, Egypt

Location

MeSH Terms

Conditions

Acute Coronary Syndrome; Metabolic Syndrome

Condition Hierarchy (Ancestors)

Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Insulin Resistance; Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Usama Ahmed Arafa, MD

  unaffillated

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Mariam Adeeb Samy, Resident

CONTACT

01202515622; mariam_adeeb_post@med.sohag.edu.eg

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident

Study Record Dates

• First Submitted: March 17, 2026
• First Posted: March 23, 2026
• Study Start: May 5, 2026
• Primary Completion (Estimated): November 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: May 6, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)